BeOne Medicines AG (ONC)
Health Care ยท Pharmaceutical Preparations
ONC is listed on Nasdaq, where its shares have traded since February 3, 2016. It represents shares of BeOne Medicines AG. SentiSense covers it in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
About BeOne Medicines AG
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Latest reported results
BeOne Medicines AG reported revenue of $1.71 billion for Q2 FY2026, up 29.6% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 276 institutions reported holding ONC, with 35.0 million shares worth $9.9 billion in aggregate. The largest reported holders were Baker Bros. Advisors, Capital Group and Primecap Management Co. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on ONC
- ONC sentiment: whether news and social coverage of BeOne Medicines AG leans bullish or bearish, and the stories driving it.
- ONC ownership: all 276 reporting institutions, plus insider and congressional trades.
- ONC financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does BeOne Medicines AG do?
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics.
What sector is ONC in?
SentiSense classifies BeOne Medicines AG in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ONC stock trade?
ONC is listed on Nasdaq, where its shares have traded since February 3, 2016. It represents shares of BeOne Medicines AG.
Who is the CEO of BeOne Medicines AG?
John V. Oyler is the chief executive officer of BeOne Medicines AG.